Beta Drugs Private Limited is a custom manufacturing and dedicated facility. Our Oncology unit dedicated to manufacturing of our leading anticancer cyto-toxics. We have achieved excellence in Formulations’ and Lypholization technology. We have strength in capacity building in sterile liquid ampule/vial, dry powder facilities and tablets and capsules unit.

Our future focus is on self reliance in Biotech and Bio-similar segments, which we have already initiated with the major business tie-ups with Reliance Life Sciences. Our first major launch is Pegfilgrastim (ADFILL),which is  required in majority of cancer patients.

Our future focus is on self reliance in Biotech and Bio-similar segments, which we have already initiated with the major business tie-ups with Reliance Life Sciences. Our first major launch is Pegfilgrastim (ADFILL),which is  required in majority of cancer patients. Further, with the launch series of biosimilars like  Rituximab, Trastuzumab, Bevacizumab ,the group turnover will cross USD  2000 million.By 2023, we are putting our dedicated effort to start our own biotech. / Biosimilar productions and exports.